We recently published a list of 11 Best Bear Market Stocks To Invest In Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best bear market stocks ...

William Blair reduced their FY2024 EPS estimates for shares of AbbVie in a research note issued on Tuesday, January 21st.

We recently compiled a list of the 10 Best Halal Dividend Stocks To Invest In. In this article, we are going to take a look ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $170.67 which represents a slight increase of $1.47 or 0.87% from the prior close of $169.2. The stock opened at $170.46 and touched a ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for AbbVie in a report released on Tuesday, ...

AbbVie, Inc. (ABBV) and Neomorph, Inc. announced Thursday a collaboration and option-to-license agreement to develop novel molecular ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target ...

AbbVie Inc. closed $31.77 below its 52-week high ($207.32), which the company reached on October 31st.

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $171.56 which represents a decrease of $-2.14 or -1.23% from the prior close of $173.7. The stock opened at $172.88 and touched a ...

AbbVie Inc. closed 18.39% short of its 52-week high of $207.32, which the company achieved on October 31st.